M2 Training (6 months)
🔬 Research area
Study on hematopoietic stem cells and their microenvironment in homeostatic conditions, under irradiation, or leukemia
🎓 Doctoral School : HOB Paris-Cité
🏢 Host Laboratory
LSHL – Laboratoire des cellules Souches Hématopoïétiques et des Leucémies
CEA (JACOB/iRCM/SCSR) – INSERM UMR 1274, 18 route du Panorama
92265 Fontenay-aux-Roses cedex
Team Leader : Françoise PFLUMIO
📞 +33 (0)1 46 54 86 17
Mentor : Stéphanie MORENO, PhD
📞 +33 (0)1 46 54 86 33
Topic : Drug- or cellular-based therapy of irradiation-induced hematopoietic syndrome
Keywords : irradiation, stem cells, irradation-induced hematopietic syndromeSummary (English)
The M2 project proposes to test and understand the mechanisms through industrial and clinical collaborations, of new drugs and cell therapies to improve hematopoietic recovery after irradiation.
The consequences of accidental or deliberate high-dose irradiation (IR) can be dramatic,
including a significant number of injuries and deaths if no therapeutic intervention is offered.
There are also non-accidental cases of high-dose irradiation, which may be medical in nature,
as part of the conditioning of patients for bone marrow (BM), hematopoietic stem cells (HSC)
or blood stem cell (BSC) transplantation, to treat diseases such as acquired bone marrow
aplasia, acute myeloblastic leukemia (AML) or hereditary aplastic anemia.
These high doses of IR delivered to the whole body or over a large volume are the cause of an Acute Radiation Syndrome (ARS), which mainly affects hematological (blood, bone marrow), gastrointestinal and neurovascular tissues. Hematopoietic syndrome (HS) is a major component of ARS. It develops after total body irradiation (TBI) with doses above 1 Gy. HS is
characterized by partial or total destruction of HSC and their environment in BM. The
therapeutic management of HS is based on medical treatments using growth factors to stimulate residual hematopoiesis, but these may be ineffective in cases of severe damage to the BM. HSC transplantation is then the best treatment, but it is invasive, not always feasible due to a lack of donors, and its success rate remains extremely low due in particular to severe side-effects (risk of graft-versus host disease).
It is therefore essential to develop new therapeutic methods to treat highly irradiated patients as quickly as possible after exposure to radiation and with minimal side effects, and thus reduce consequences of the hematopoietic ARS.
Comments